These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32517638)

  • 1. Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: Case report.
    Amer-Salas N; González-Morcillo G; Rodríguez-Camacho JM; Cladera-Serra A
    J Oncol Pharm Pract; 2021 Jan; 27(1):244-249. PubMed ID: 32517638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nelarabine-associated reversible Guillain-Barré-like syndrome or myelopathy in an adult patient with primary refractory T-lymphoblastic lymphoma.
    Lalayanni C; Baldoumi E; Papayiannopoulos S; Tziola K; Saloum R; Anagnostopoulos A
    Curr Probl Cancer; 2017; 41(2):138-143. PubMed ID: 28169005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma.
    Karthik U; Motwani J
    J Oncol Pharm Pract; 2024 Apr; 30(3):594-596. PubMed ID: 38105625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system neurotoxicity associated with nelarabine in T-cell acute lymphoblastic leukemia.
    Pehlivan UA; Gürkan E; Açar İH; Bıçakcı YK
    J Oncol Pharm Pract; 2023 Jan; 29(1):246-251. PubMed ID: 35593112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nelarabine-induced peripheral and central neurotoxicity: can sequential MRI brain imaging help to define its natural history?
    Ewins K; Malone A; Phelan E; Webb D; McHugh JC; Smith O
    Br J Haematol; 2017 Oct; 179(2):294-297. PubMed ID: 28961308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric T-ALL complicated by irreversible nelarabine neurotoxicity.
    Kanayama T; Imamura T; Nakagawa N; Osone S; Hosoi H
    Pediatr Int; 2017 Jul; 59(7):843-845. PubMed ID: 28745456
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
    Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
    Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MR imaging in nelarabine-induced myelopathy.
    Dua SG; Jhaveri MD
    J Clin Neurosci; 2016 Jul; 29():205-6. PubMed ID: 26899359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
    Candoni A; Lazzarotto D; Petruzzellis G
    Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
    Dyakonova YY; Bydanov OI; Popov AM; Olshanskaya YV; Boichenko EG; Aleynikova OV; Maschan MA; Shelikhova LN; Litvinov DV; Khachatryan LA; Ponomareva NI; Fechina LG; Novichkova GA; Pashanov ED; Karachunskiy AI
    Ter Arkh; 2018 Aug; 90(7):38-50. PubMed ID: 30701921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nelarabine-induced myelopathy in patients undergoing allogeneic hematopoietic cell transplantation: a report of three cases.
    Fukuta T; Tanaka T; Hashimoto T; Isahaya K; Kubo Y; Yamano Y; Satomi K; Hiraoka N; Shirakawa N; Arakawa A; Ogawa C; Nishimura N; Aoki J; Ito A; Inamoto Y; Kim SW; Fukuda T
    Int J Hematol; 2023 Jun; 117(6):933-940. PubMed ID: 36705847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.
    Kumamoto T; Goto H; Ogawa C; Hori T; Deguchi T; Araki T; Saito AM; Manabe A; Horibe K; Toyoda H
    Int J Hematol; 2020 Nov; 112(5):720-724. PubMed ID: 32761462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe, reversible nelarabine-induced neuropathy and myelopathy.
    Alberti P; Parma M; Pioltelli P; Pogliani EM; Terruzzi E; Stasia A; Doni E; Cecchetti C; Cavaletti G
    J Peripher Nerv Syst; 2016 Sep; 21(3):154-6. PubMed ID: 27117493
    [No Abstract]   [Full Text] [Related]  

  • 14. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
    Abaza Y; M Kantarjian H; Faderl S; Jabbour E; Jain N; Thomas D; Kadia T; Borthakur G; D Khoury J; Burger J; Wierda W; O'Brien S; Konopleva M; Ferrajoli A; Kebriaei P; Dabaja B; Kornblau S; Alvarado Y; Daver N; Pemmaraju N; Bose P; Thompson P; Al Azzawi H; Kelly M; Garris R; Jain P; Garcia-Manero G; Cortes J; Ravandi F
    Am J Hematol; 2018 Jan; 93(1):91-99. PubMed ID: 29047158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
    Boddu PC; Senapati J; Ravandi-Kashani F; Jabbour EJ; Jain N; Ayres M; Chen Y; Keating MJ; Kantarjian HM; Gandhi V; Kadia TM
    Cancer; 2023 Feb; 129(4):580-589. PubMed ID: 36448227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions.
    Miller LH; Maxa KL; Winter SS; Gossai NP
    Expert Rev Anticancer Ther; 2023; 23(12):1229-1236. PubMed ID: 37850259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: Case report and review of literature.
    Ngo D; Patel S; Kim EJ; Brar R; Koontz MZ
    J Oncol Pharm Pract; 2015 Aug; 21(4):296-300. PubMed ID: 24664478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
    DeAngelo DJ
    Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.
    Dunsmore KP; Winter SS; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Rabin KR; Zweidler-Mckay PA; Raetz EA; Loh ML; Schultz KR; Winick NJ; Carroll WL; Hunger SP
    J Clin Oncol; 2020 Oct; 38(28):3282-3293. PubMed ID: 32813610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nelarabine: a novel purine antimetabolite antineoplastic agent.
    Buie LW; Epstein SS; Lindley CM
    Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.